I posted this on SI. I only skimmed through the call for pertinent discussion on Roxadustat so can't comment on anything else (its 1:50 in total length).
The presentation was straight forward not too much depth (starts around 32 min mark +/-)
There were a couple questions in the Q&A 1. (Around 1:20 mark +/-) About the CV safety. For dialysis they are looking at superiority over EPO (meta analysis of all the studies), powered for 20% safety improvement but that is not required for approval. For the non-dialysis saying they should be equal safe as placebo. 2. (Around 1:28 mark +/-) Shortening time to US filing (from 2018)? Said very unlikely only said event driven trial & need sufficient number to do CV analysis (no talk of interim). 3. (Around 1:30 mark +/-) Given less aggressive hemoglobin targets today how it effects potential to show CV risk reduction. Think doesn't matter much if anything works to advantage.
Market Data 
Markets 
AI
